|

Camizestrant Clinical Trials

4 actively recruiting trials across 4 locations

Also known as: AZD9833

Pipeline

Phase 3: 3Phase 1/2: 1

Top Sponsors

  • AstraZeneca4

Indications

  • Breast Cancer4
  • Cancer4
  • Breast Cancer, Early Breast Cancer2
  • High-grade Serous Ovarian Cancer (HGSOC)1
  • ER+ HER2- Advanced Breast Cancer1

Birmingham, Alabama1 trial

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Research Site

Phase 3

Dothan, Alabama1 trial

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Research Site

Phase 3

Gilbert, Arizona1 trial

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Research Site

Phase 3

St Louis, Missouri1 trial

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Research Site

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.